ORGANOVO HOLDINGS, INC. (42)

Browse by Contract Category

Contracts

Organovo Holdings, Inc. 2022 Equity Incentive Plan (Filed With SEC on October 14, 2022)
Settlement and Patent License Agreement, dated February 22, 2022, by and between Organovo Holdings Inc. and BICO Group AB (Filed With SEC on June 10, 2022)
Description of Securities (Filed With SEC on June 10, 2022)
Amended and Restated Lease Agreement dated November 23, 2020, between Organovo, Inc., as Tenant, and San Diego Inspire 2, LLC, as Landlord, as amended by First Amendment to... (Filed With SEC on November 19, 2021)
Form of Release Agreement by Keith Murphy in favor of the Companys directors and officers (Filed With SEC on July 15, 2020)
First Amendment to Merger Agreement, dated January 26, 2020, by and among Organovo, Merger Sub and Tarveda (Filed With SEC on January 29, 2020)
License Agreement, dated September 14, 2016, by and between Tarveda Therapeutics, Inc. and Madrigal Pharmaceuticals, Inc (Filed With SEC on December 23, 2019)
Amendment #5 dated October 4, 2021 to Consulting Agreement dated August 25, 2021 by and between Company and Danforth Advisors LLC (Filed With SEC on October 6, 2021)
Organovo Holdings, Inc. Amended and Restated 2012 Equity Incentive Plan (As Amended & Restated on October 5, 2021) (Filed With SEC on October 6, 2021)
Description of Securities (Filed With SEC on June 15, 2021)
Organovo Holdings, Inc. Amended and Restated 2012 Equity Incentive Plan (Filed With SEC on March 10, 2021)
Organovo Holdings, Inc. 2021 Inducement Equity Incentive Plan (Filed With SEC on March 10, 2021)
Offer Letter, dated December 28, 2020, between the Company and Tom Jurgensen (Filed With SEC on February 8, 2021)
Intercompany Agreement, dated December 28, 2020, by and among Organovo Holdings, Inc., Organovo, Inc. and Viscient Biosciences, Inc (Filed With SEC on December 31, 2020)
Engagement Agreement, dated July 23, 2020, by and between Organovo and Optima Law Group of San Diego (Filed With SEC on November 5, 2020)
Offer Letter, dated September 15, 2020, between the Company and Jeffrey N. Miner (Filed With SEC on November 5, 2020)
Consulting Agreement, dated August 25, 2020, by and between Organovo and Danforth Advisors (Filed With SEC on November 5, 2020)
Consulting Agreement, dated September 15, 2020, by and between Organovo and Multi Dimensional Bio Insight LLC (Filed With SEC on November 5, 2020)
Form of Separation Agreement and Release with the Companys officers (Filed With SEC on July 15, 2020)
Form of Separation and Mutual Release Agreement with the Companys directors (Filed With SEC on July 15, 2020)
Cooperation Agreement, dated July 14, 2020, between the Company and Keith Murphy (Filed With SEC on July 15, 2020)
Description of Securities (Filed With SEC on May 28, 2020)
Amendment to Organovo Holdings, Inc. Severance and Change in Control Plan, dated May 19, 2020 (Filed With SEC on May 20, 2020)
Tarveda Therapeutics, Inc. (formerly Blend Biosciences, Inc.) 2011 Stock Incentive Plan (Filed With SEC on December 23, 2019)
Fourth Amendment to Lease, dated May 31, 2019, by and between BMR-134 Coolidge Avenue LLC and Tarveda Therapeutics, Inc (Filed With SEC on December 23, 2019)
Loan and Security Agreement, dated March 29, 2019, among Oxford Finance LLC, the Lenders named therein, and Tarveda Therapeutics, Inc (Filed With SEC on December 23, 2019)
Warrant to Purchase Stock issued by Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) to Comerica Bank, dated February 8, 2012 (Filed With SEC on December 23, 2019)
Warrant to Purchase Stock issued by Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) to Comerica Bank, dated November 19, 2013 (Filed With SEC on December 23, 2019)
First Amendment to Lease, dated February 23, 2012, by and between BMR-134 Coolidge Avenue LLC and Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) (Filed With SEC on December 23, 2019)
Second Amendment to Lease, dated January 8, 2013, by and between BMR-134 Coolidge Avenue LLC and Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) (Filed With SEC on December 23, 2019)
Third Amendment to Lease, dated April 19, 2016, by and between BMR-134 Coolidge Avenue LLC and Tarveda Therapeutics, Inc (Filed With SEC on December 23, 2019)
Employment Agreement, dated March 2, 2015, by and between Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) and Andrew J. Fromkin (Filed With SEC on December 23, 2019)
Lease, dated December 12, 2011, by and between BMR-134 Coolidge Avenue LLC and Tarveda Therapeutics, Inc. (formerly Blend Therapeutics, Inc.) (Filed With SEC on December 23, 2019)
Fifth Amended and Restated Investor Rights Agreement, dated December 12, 2019, by and between Tarveda Therapeutics, Inc. and the stockholders party thereto (Filed With SEC on December 23, 2019)
First Amendment to Employment Agreement, dated April 6, 2016, by and between Tarveda Therapeutics, Inc. and Andrew J. Fromkin (Filed With SEC on December 23, 2019)
Employment Agreement, dated December 19, 2017, by and between Tarveda Therapeutics, Inc. and Brian Roberts (Filed With SEC on December 23, 2019)
Employment Agreement, dated July 27, 2018, by and between Tarveda Therapeutics, Inc. and Jeffrey Bloss (Filed With SEC on December 23, 2019)
Form of Tarveda Therapeutics, Inc. Nondisclosure, Noncompetition and Assignment of Intellectual Property Agreement (Filed With SEC on December 23, 2019)
Form of Lock-Up Agreement, by and among Tarveda, Organovo and certain directors and officers of Tarveda and Organovo (Filed With SEC on December 16, 2019)
Agreement and Plan of Merger and Reorganization, dated as of December 13, 2019, by and among Organovo, Merger Sub and Tarveda (Filed With SEC on December 16, 2019)
Form of Support Agreement, by and between Tarveda, Organovo and certain directors and officers of Organovo (Filed With SEC on December 16, 2019)
Form of Support Agreement, by and between Organovo, Tarveda and certain directors, officers and stockholders of Tarveda (Filed With SEC on December 16, 2019)